Literature DB >> 23595559

Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.

Reeva Aggarwal1, Jingwei Lu, Suman Kanji, Manjusri Das, Matthew Joseph, Maryam B Lustberg, Alo Ray, Vincent J Pompili, Charles L Shapiro, Hiranmoy Das.   

Abstract

Innate immune system has been known to play an important role in inhibiting the malignant transformation, tumor progression and invasion. However, the mechanistic basis remains ambiguous. Despite polyclonality of human γδ T cells, Vγ2Vδ2 T cell subset was shown to recognize and limit the growth of various tumors at various degrees. The differential recognition of the tumor cells by Vγ2Vδ2 T cells are yet to be defined. Our study reveals that γδ T cells limit in vitro growth of most breast tumor cells, such as SkBr7 (HER2+), MCF7 (ER+) and MDA-MB-231 (ER-) by inhibiting their survival and inducing apoptosis, except BrCa-MZ01 (PR+) cells. To investigate detail mechanisms of antineoplastic effects, we found that cell death was associated with the surface expression levels of MICA/B and ICAM1. Molecular signaling analysis demonstrated that inhibition of cell growth by γδ T cells was associated with the lower expression levels of cell survival-related molecules such as AKT, ERK and concomitant upregulation of apoptosis-related molecules, such as PARP, cleaved caspase 3 and tumor suppressor genes PTEN and P53. However, opposite molecular signaling was observed in the resistant cell line after coculture with γδ T cells. In vivo, antineoplastic effects of γδ T cells were also documented, where tumor growth was inhibited due to the downregulation of survival signals, strong induction of apoptotic molecules, disruption of microvasculature and increased infiltration of tumor associated macrophages. These findings reveal that a complex molecular signaling is involved in γδ T cell-mediated antineoplastic effects.
Copyright © 2013 UICC.

Entities:  

Keywords:  NOD/SCID mice; Vγ2Vδ2 T cell; angiogenesis; apoptosis; breast cancer; cell survival; xenotransplant

Mesh:

Substances:

Year:  2013        PMID: 23595559      PMCID: PMC3939063          DOI: 10.1002/ijc.28217

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The origin and function of tumor-associated macrophages.

Authors:  A Mantovani; B Bottazzi; F Colotta; S Sozzani; L Ruco
Journal:  Immunol Today       Date:  1992-07

3.  Mechanisms of Vdelta1 gammadelta T cell activation by microbial components.

Authors:  Hiranmoy Das; Masahiko Sugita; Michael B Brenner
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

Review 4.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.

Authors:  A Choudhary; F Davodeau; A Moreau; M A Peyrat; M Bonneville; F Jotereau
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

6.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

7.  V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors.

Authors:  I Bank; M Book; M Huszar; Y Baram; I Schnirer; H Brenner
Journal:  Clin Immunol Immunopathol       Date:  1993-04

8.  MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Authors:  Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

9.  Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules.

Authors:  Jingwei Lu; Reeva Aggarwal; Suman Kanji; Manjusri Das; Matthew Joseph; Vincent Pompili; Hiranmoy Das
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

10.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.

Authors:  Paulo C Rodriguez; Claudia P Hernandez; David Quiceno; Steven M Dubinett; Jovanny Zabaleta; Juan B Ochoa; Jill Gilbert; Augusto C Ochoa
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

View more
  17 in total

1.  Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer.

Authors:  Jieti Wang; Chao Lin; He Li; Ruochen Li; Yifan Wu; Hao Liu; Heng Zhang; Hongyong He; Weijuan Zhang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2017-07-24       Impact factor: 8.110

2.  Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma.

Authors:  Bin Shao; Enzhong Liu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

3.  Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.

Authors:  L Bizzozero; D Cazzato; D Cervia; E Assi; F Simbari; F Pagni; C De Palma; A Monno; C Verdelli; P R Querini; V Russo; E Clementi; C Perrotta
Journal:  Cell Death Differ       Date:  2013-12-06       Impact factor: 15.828

4.  Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.

Authors:  Aneta Zysk; Mark O DeNichilo; Vasilios Panagopoulos; Irene Zinonos; Vasilios Liapis; Shelley Hay; Wendy Ingman; Vladimir Ponomarev; Gerald Atkins; David Findlay; Andrew Zannettino; Andreas Evdokiou
Journal:  Cancer Lett       Date:  2016-11-16       Impact factor: 8.679

Review 5.  The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.

Authors:  Mateusz Legut; David K Cole; Andrew K Sewell
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

6.  Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes.

Authors:  Baoai Han; He Zhang; Yuying Zhu; Xingxing Han; Zhiyong Wang; Zicong Gao; Yue Yuan; Ruinan Tian; Fei Zhang; Ruifang Niu
Journal:  Aging (Albany NY)       Date:  2020-07-10       Impact factor: 5.682

Review 7.  Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

8.  Biologically Active α-Amino Amide Analogs and γδ T Cells-A Unique Anticancer Approach for Leukemia.

Authors:  Ahmed Al Otaibi; Subuhi Sherwani; Salma Ahmed Al-Zahrani; Eida Mohammed Alshammari; Wahid Ali Khan; Abdulmohsen Khalaf D Alsukaibi; Shahper Nazeer Khan; Mohd Wajid Ali Khan
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 6.244

Review 9.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

10.  Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia.

Authors:  Gabrielle M Siegers; Indrani Dutta; Raymond Lai; Lynne-Marie Postovit
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.